US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious
US regulators have endorsed multi-cancer early detection (MCED) blood tests for the first time. A US Food and Drug Administration (FDA) panel voted to recommend Grail's Galleri test for premarket approval. This marks a landmark decision for the emerging field. The tests aim to find cancer signs in healthy individuals by analyzing abnormal molecules in bodily fluids.
The FDA panel's vote for Grail's Galleri test is a significant step for MCED technology. It validates the concept of detecting multiple cancers from a single blood sample. This regulatory backing could accelerate research and development in the field, moving these tests closer to wider clinical use.
For Hong Kong, the immediate impact is limited. Doctors there remain cautious about the clinical value of MCED tests. Wider adoption in Hong Kong faces challenges, despite growing interest. Local healthcare providers will demand more data before integrating these tests into standard practice.
The thing to watch is how Asian regulators respond. If a major Asian market like China or Japan grants similar premarket approval, it would signal a faster path to adoption across the region. This would open new market opportunities for companies developing these diagnostics.
Related reading
6 stories
Over 1 in 10 Frauds Now Involve an Identity That Is Not Real
DBS, Avaloq Expand Partnership as Wealth Business Targets S$1 Trillion in Assets
Uber shuts down FlyTaxi, second metered cab platform it acquired in Hong Kong
The Uptake | Shared advantage
China rebuffs AI slowdown calls ahead of Trump-Xi summit: 5 things to know
